ATE504309T1 - Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis - Google Patents

Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis

Info

Publication number: ATE504309T1
Authority: AT; Austria
Prior art keywords: cervicitis; situ; pharmaceutical composition; oxytocin; preparing
Prior art date: 2001-02-28

Application number

AT02701842T

Other languages

English (en)

Inventor

Kerstin Uvnaes-Moberg

Thomas Lundeberg

Original Assignee

Kerstin Uvnaes-Moberg

Thomas Lundeberg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-28

Filing date

2002-02-28

Publication date

2011-04-15

2002-02-28 Application filed by Kerstin Uvnaes-Moberg, Thomas Lundeberg filed Critical Kerstin Uvnaes-Moberg

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE504309T1 publication Critical patent/ATE504309T1/de

Links

208000006374 Uterine Cervicitis Diseases 0.000 title abstract 3
206010008323 cervicitis Diseases 0.000 title abstract 3
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title abstract 2
101800000989 Oxytocin Proteins 0.000 title abstract 2
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title abstract 2
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 2
229960001723 oxytocin Drugs 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
208000009458 Carcinoma in Situ Diseases 0.000 title 1
201000004933 in situ carcinoma Diseases 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
238000011065 in-situ storage Methods 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT02701842T 2001-02-28 2002-02-28 Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis ATE504309T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0100684A SE0100684D0 (sv)	2001-02-28	2001-02-28	New subject-matter
PCT/SE2002/000362 WO2002067974A1 (en)	2001-02-28	2002-02-28	Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

Publications (1)

Publication Number	Publication Date
ATE504309T1 true ATE504309T1 (de)	2011-04-15

Family

ID=20283165

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02701842T ATE504309T1 (de)	2001-02-28	2002-02-28	Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis

Country Status (7)

Country	Link
US (1)	US7405200B2 (de)
EP (1)	EP1370277B1 (de)
JP (1)	JP2004527496A (de)
AT (1)	ATE504309T1 (de)
DE (1)	DE60239670D1 (de)
SE (1)	SE0100684D0 (de)
WO (1)	WO2002067974A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0001440D0 (sv) *	2000-04-18	2000-04-18	Entretech Medical Ab	A drug against climacteric disorders
AR038085A1 (es) *	2002-12-27	2004-12-29	Univ Nac Quilmes	Analogos de 1-desamino-8-d-arginina vasopresina
CA2699100A1 (en) *	2007-09-11	2009-04-02	Dorian Bevec	Use of a peptide as a therapeutic agent
CA2699169A1 (en) *	2007-09-11	2009-04-16	Mondobiotech Laboratories Ag	Therapeutic uses of intermedin 47 and 53 peptides
WO2009033820A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
EP2197463A2 (de) *	2007-09-11	2010-06-23	Mondobiotech Laboratories AG	Verwendung von rgdspasskp und optional angiotensin-ii als therapeutische mittel zur behandlung von z.b. infektionen mit s. pneumoniae
CA2704724A1 (en) *	2007-09-11	2009-04-16	Mondobiotech Laboratories Ag	5use of a peptide as a therapeutic agent
SE536091C2 (sv) *	2011-04-14	2013-04-30	Pep Tonic Medical Ab	Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US11414459B2 (en)	2017-09-28	2022-08-16	Kinoxis Therapeutics Pty Ltd	Metabolite inspired selective oxytocin receptor agonists
JP7390031B2 (ja) *	2018-12-27	2023-12-01	国立大学法人金沢大学	オキシトシン誘導体及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE430885B (sv) *	1980-03-24	1983-12-19	Ferring Ab	Oxytocin-derivat
CS255616B1 (cs) *	1986-07-18	1988-03-15	Petr Simek	Způsob výroby (2-0-metyltyrosin)deamino-1-karbaoxytocinu
DE4229878A1 (de) *	1992-09-04	1994-03-10	Knauf Siegfried	Neues Medikament "Oxytocin" zur Bekämpfung der Zuckerkrankheit Typ 1
DE4236293A1 (en)	1992-10-23	1993-03-04	Siegfried Knauf	Use of oxytocin, vasopressin and endorphins - for treatment and prevention of e.g. immunological, neurological and organ diseases and conditions caused by pituitary disorder
DE4244639A1 (de) *	1992-10-23	1994-07-07	Knauf Siegfried	Medikament bzw. Medikamentenzusammensetzung
GB9326354D0 (en)	1993-12-23	1994-02-23	British Aerospace	Methods and apparatus for the testing,monitoring and improvement of manufacturing process effectiveness
SE9701161D0 (sv) *	1997-03-27	1997-03-27	Karolinska Innovations Ab	New use I
SE9701162D0 (sv) *	1997-03-27	1997-03-27	Karolinska Innovations Ab	New use II
SE9803272D0 (sv) *	1998-09-25	1998-09-25	Kerstin Uvnaes Moberg	A drug for cell regeneration
SE0001440D0 (sv)	2000-04-18	2000-04-18	Entretech Medical Ab	A drug against climacteric disorders
SE0102910D0 (sv) *	2001-08-31	2001-08-31	Moberg Kerstin Uvnaes	New use

2001
- 2001-02-28 SE SE0100684A patent/SE0100684D0/xx unknown
2002
- 2002-02-28 US US10/469,255 patent/US7405200B2/en not_active Expired - Lifetime
- 2002-02-28 DE DE60239670T patent/DE60239670D1/de not_active Expired - Lifetime
- 2002-02-28 WO PCT/SE2002/000362 patent/WO2002067974A1/en not_active Ceased
- 2002-02-28 AT AT02701842T patent/ATE504309T1/de not_active IP Right Cessation
- 2002-02-28 EP EP02701842A patent/EP1370277B1/de not_active Expired - Lifetime
- 2002-02-28 JP JP2002567340A patent/JP2004527496A/ja active Pending

Also Published As

Publication number	Publication date
JP2004527496A (ja)	2004-09-09
EP1370277A1 (de)	2003-12-17
EP1370277B1 (de)	2011-04-06
SE0100684D0 (sv)	2001-02-28
US7405200B2 (en)	2008-07-29
US20040176284A1 (en)	2004-09-09
DE60239670D1 (de)	2011-05-19
WO2002067974A1 (en)	2002-09-06

Similar Documents

Publication	Publication Date	Title
DE60031396D1 (de)	2006-11-30	Zubereitung zur behandlung von einer neurologischen erkrankung
ATE204754T1 (de)	2001-09-15	Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
ATE433959T1 (de)	2009-07-15	Analoge von kokain
ATE248599T1 (de)	2003-09-15	Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE69736183D1 (de)	2006-08-03	Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
BR0010524A (pt)	2002-05-28	Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
IL197686A0 (en)	2011-07-31	Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
ATE242238T1 (de)	2003-06-15	Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
EP0948327A4 (de)	2003-04-02	Antidiabetische mittel
ATE495187T1 (de)	2011-01-15	Dalda-analoge und ihre verwendung
ATE438630T1 (de)	2009-08-15	5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE504309T1 (de)	2011-04-15	Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE69824576D1 (de)	2004-07-22	Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE368455T1 (de)	2007-08-15	Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69328025D1 (de)	2000-04-13	Dorsalgewebe beeinflussender faktor und zusammensetzungen
ATE218860T1 (de)	2002-06-15	Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
ATE369348T1 (de)	2007-08-15	Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE69829202D1 (de)	2005-04-07	Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE231131T1 (de)	2003-02-15	Verbindungen mit wachtumshormon freisetzenden eigenschaften
ATE246518T1 (de)	2003-08-15	Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
EP1401467A4 (de)	2005-07-20	Alpha-fetoprotein-peptide und ihre verwendung
DE69233725D1 (de)	2008-03-27	Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
NO983177L (no)	1998-07-10	Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE60015791D1 (de)	2004-12-16	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE252383T1 (de)	2003-11-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen

Legal Events

Date	Code	Title	Description
2011-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties